**10. Future pipeline in phase III development**

There has been emergence and increase of MDR pathogens. Efforts have been made toward adequate treatment, daily de-escalation regimen as well as antibiotic stewardship programs. The pipeline for the new drugs is still sparse. **Table 7** illustrates the antibiotics that are in the phase 3 trials. Only very few have an expected activity against the CDC urgent threat potential (**Table 7**).
